Monday, September 28, 2015
To encourage junior faculty at African academic institutions to pursue research careers, the NIH is awarding up to $36.5 million over five years in the next phase of the Medical Education Partnership Initiative (MEPI). Sub-Saharan Africa bears almost a quarter of the global disease burden, yet has only 3% of the world’s health workforce, according to the World Health Organization.
Winners have been announced for the Prostate Cancer DREAM Challenge, the first research challenge in prostate cancer to marry crowdsourcing with data sharing, paving a new way to tackle key research questions about metastatic castration-resistant prostate cancer (mCRPC), an advanced form of the disease with poor outcomes.
The number of mobile health applications available to consumers now surpasses 165,000, as developers incorporate innovative data collection features linked to sensors and wearables, according to a new report released by the IMS Institute for Healthcare Informatics. While most available apps focus on overall wellness, healthcare systems and professionals are expressing greater interest and excitement in broader app use as barriers to mainstream adoption of mHealth are removed—especially in the area of chronic disease management.
Optimal Strategix Group (OSG), based in Newtown, Pa., has launched its CAVII app, available for download in the Apple App Store. CAVII is an iOS-based clinical study matching and analytics platform. Ushering in a new era of patient engagement, CAVII’s aim is to revolutionize clinical studies through the use of analytics for superior patient matching. Through CAVII, clinical studies could become more cost-effective, efficient and ultimately more engaging and insightful for patients and clinicians.
A strong and growing desire to solicit feedback directly from patients, experienced participants and their support network is prompting many sponsors and CROs to assess, plan and implement patient advisory panels.
Certara, a global biosimulation technology-enabled drug development company, and Paidion Research, a Durham, N.C.-based pediatric CRO, have partnered to promote more efficient and reliable drug development for pediatric patients. The partnership harnesses Certara’s biosimulation (modeling and simulation) and regulatory writing capabilities with Paidion’s regulatory strategy and pediatric clinical trial management expertise to address the critical challenges of bringing new therapies to children.
With shrinking R&D pipelines and mounting costs involved in drug development, it is becoming increasingly important for pharmaceutical companies to implement suitable life cycle management (LCM) strategies in order to maximize revenues and the lifespan of their portfolios, according to business intelligence provider GBI Research.